Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Exclusion Criteria

• •1. Patients with heart disease above grade II (including grade II) identified by New York Heart Association (NYHA) scores;
• •2. Brain metastasis;
• •3. Recurrence or metastasis within 6 months after capecitabine withdrawal;
• •4. Recurrence or metastasis within 6 months after platinum withdrawal;
• •5. Progression in the treatment, recurrence or metastasis of paclitaxel (including albumin paclitaxel) within 6 months;
• •6. Patients required clinical intervention with gastrointestinal bleeding, gastrointestinal obstruction and non-feeding;
• •7. Patients who had Grade 2 or above Peripheral neuropathy;
• •8. Patients with severe systemic infection or other serious diseases;
• •9. Patients allergic to or intolerant of chemotherapeutic drugs or their adjuvants;
• •10. Patients with other malignant tumors in the past five years, except for cured cervical carcinoma in situ and non-melanoma skin cancer;
• •11. Pregnancy or lactation, as well as reproductive age patients who refused to take appropriate contraceptive measures in the trial;
• •12. Participation in any trial drug treatment or another interventional clinical trial 30 days before first dose was given;
• •13. The researchers considered the patients who were not suitable for enrollment.